Asahi Songwon Colors Limited — Q4 FY25 earnings call

Call held 12 May 2025

Management summary

Asahi Songwon delivered a strong FY25 performance, marked by significant revenue and EBITDA growth, a return to PAT positivity, and substantial debt reduction. The company benefited from improved operating cash flows and working capital efficiency. While facing challenges from API price crashes and tepid pigment demand, strategic initiatives in AZO and API segments, including capacity expansion and new product launches, are expected to drive future growth and margin expansion.

Highlights

  • FY25 Revenue increased by 32% to 566 crores (from 429 crores in FY24).

  • FY25 EBITDA grew by 185% to 60 crores (from 21 crores in FY24).

  • FY25 EBITDA margins doubled from 5% to 10%.

  • FY25 PAT turned positive at 17 crores (from negative in FY24).

  • Operating cash flow improved to 57 crores positive (from 9 crores positive in FY24).

  • Total debt reduced from 200 crores (March 2024) to 160 crores (March 2025).

  • Working capital days reduced from ~130 days to ~102 days.

Concerns

  • API product prices, particularly Pregabalin, have crashed, with a ~15% decrease in prices for most products.

  • General demand scenario in the pigment business is 'not very robust' and 'tepid'.

  • The industry is currently experiencing 'turbulent times with uncertainties and lots of volatility'.

Key financials

  1. Revenue ₹566 Cr +32%YoY
  2. EBITDA ₹60 Cr +185%YoY
  3. EBITDA Margin 10%
  4. PAT ₹17 Cr
  5. Operating Cash Flow ₹57 Cr +533%YoY
  6. Total Debt ₹160 Cr -20%YoY

What they filed

Q1 FY27: revenue up 28.3%, net profit up 183.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue99 94 107 106 73 −26%74 −21%91 −15%136 +28%
EBITDA11 9 14 9 6 −45%7 −22%13 −7%24 +167%
Net profit6 5 9 6 4 −33%4 −20%10 +11%17 +183%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • AZO Pigment Business
    64% Capacity Utilization (FY24)80% Capacity Utilization (Target FY26)₹70 Cr Top Line (FY24)₹90 Cr Top Line (Target FY26)8% EBITDA (Target FY26)20% Export Mix (Target FY26)
  • API Business
    ₹10.5 Cr EBITDA (FY25)₹5 Cr EBITDA (FY24)25% Volume Growth (FY25)10% EBITDA Margin (QoQ)
  • Blue Business
    85% Capacity Utilization

Capital allocation

high confidence
  • Capex Capex disclosed
    • Yellow pigment line capacity expansion ₹5 Cr
    The Capex is about 5 crores.
  • Debt Gross ₹160 Cr · 2.5× EBITDA
    Our total debt, which stood at 200 crores in 2024 March stood at 160 crores this March, we continue to deleverage as our cash flows show a lot of strength.
  • Liquidity Liquidity disclosed Operating cash flows from operations were 9 crores positive in 2024 have come out to 57 crores positive in 2025, due to improvement in payables, receivables and inventory levels.
    Our cash flows from operations which were 9 crores positive in 2024 have come out to 57 crores positive. In 2025. This improvement is on account of four factors, 30 crores from pockets and 25 crores, a combination of improvement in payables, receivables and inventory levels.

Guidance & targets

Revenue

  • Top Line Growth Revenue · next year · High confidence 15%
    Going forward, we look forward to a top line growth of about 15%, EBITDA growth of about 25% and PBT growth of about 65% for the next year.

    — Gokul Jaykrishna

Profitability

  • EBITDA Growth Profitability · next year · High confidence 25%
    Going forward, we look forward to a top line growth of about 15%, EBITDA growth of about 25% and PBT growth of about 65% for the next year.

    — Gokul Jaykrishna

  • PBT Growth Profitability · next year · High confidence 65%

    — Gokul Jaykrishna

  • Consolidated Percentage EBITDA Profitability · next couple of years · Medium confidence 12%
    Consolidated percentage EBITDA, we are targeting at about 12%.

    — Gokul Jaykrishna

AZO Business

  • Export Mix AZO Business · this financial year · High confidence 20-25%

    From 10% today

    you know the export business out of the ATC basket, which is currently 90 domestic, 10 export should look to about 20-25% coming from export for this financial year.

    — Gokul Jaykrishna

  • Top Client Growth AZO Business · this financial year · High confidence 25% (from 70 crores to 90 crores)

    From 70 crores today

    And our top client should be growing at about 25% from 70 crores to roughly 90 crores and the EBITDA should also be growing substantially.

    — Gokul Jaykrishna

  • Capacity Utilization AZO Business · this year · High confidence 80-85%

    From 64% today

    basically capacity utilization on the AZOs was about 64% for last year for the yellows and red put together and we are hoping to improve that to about 85 percent, 80 to 85% this year...

    — Gokul Jaykrishna

  • Top Line Growth AZO Business · this year · High confidence 26-27%
    that will improve the top line from a 70 crores to 90 crores, which is about a 26-27% growth in the top line of the AZOs...

    — Gokul Jaykrishna

  • EBITDA AZO Business · this year · High confidence 8-10%
    we are looking to have an EBITDA of 8-10%, so we should be getting about 8 crores of EBITDA.

    — Gokul Jaykrishna

  • Large Orders from Customers AZO Business · by the end of the year · High confidence 1-2 customers
    by the end of the year, yes, we should have commercial large quantity orders from one or two customers at least.

    — Arjun Jaykrishna

API Business

  • EBITDA Margins API Business · full year · High confidence 10-11%
    But going forward, the EBITDA margins we project would be in double digits, low double digits, so about 10 to 11% for the full year for the consolidated atlas performance.

    — Gokul Jaykrishna

  • Top Line Improvement API Business · full year · High confidence 25%
    And also, on the top line we should see a reasonable improvement about 25% on top line for the year...

    — Gokul Jaykrishna

Overall

  • EBITDA Improvement Overall · full year · High confidence 25%
    that means that the total overall EBITDA also should improve by about 25 odd percent if we are able to maintain 10-11% margins there.

    — Gokul Jaykrishna

ROCE

  • Return on Capital Employed ROCE · next couple of years · Medium confidence 15%

    From 10-11% today

    we would be targeting 15% ROCE over the next couple of years

    — Gokul Jaykrishna

Capacity

  • Maximum Top Line from Current Capacity Capacity · Medium confidence 750 crores
    The maximum top line from current capacity should take us to about 750 crores.

    — Gokul Jaykrishna

What to watch in Q1 FY26

Yellow Pigment Line Operationalization

Within 3-4 months (Q1/Q2 FY26)
Current Chinese equipment on its way, 3-4 months to be fully operational
Target Fully operational, adding ~40 tons capacity

Why it matters

Will contribute to capacity and volume growth in the yellow pigment segment, impacting overall AZO performance.

The Chinese equipment is already on its way and it should be fully operational within about three to four months. So, they should add about 40 tons to our existing capacity of yellow...

Risks & concerns

  • API Product Price Crash

    high

    Prices for key API products, especially Pregabalin, have crashed by ~15%, impacting profitability.

    Management acknowledged

  • Global Volatility and Uncertainties

    medium

    The company is operating in 'turbulent times with uncertainties and lots of volatility' but sees opportunities.

    Management acknowledged

  • Tepid Demand in Pigment Business

    medium

    General demand scenario in the pigment business is 'not very robust' and 'tepid'.

    Management acknowledged

  • Competition in Blue Business

    medium

    The blue business environment is challenging with strong competition and not robust demand.

    Management acknowledged

  • Pregabalin Narcotic Drug Classification Impact

    low

    Analyst inquired about the impact of Pregabalin being categorized as a narcotic drug; management stated no impact as they sell to regulated customers.

    Analyst downplayed

Q&A highlights

8 direct
Yellow pigment capacity expansion update and investment Direct
The Chinese equipment is already on its way and it should be fully operational within about three to four months. So, they should add about 40 tons to our existing capacity of yellow... The Capex is about 5 crores.

Provides specific timelines and scale of capacity addition for a key product, confirming the investment made.

Asked by Yashvi

AZO business opportunities from tariffs and profitability Direct
the opportunity for all Indian makers is thrown up, we feel that we are in a very good position to be able to take some of this opportunity... We are already seeing inquiries and what we feel is that for certain large customers... we are hoping that we will be able to reflect that into performance for the AZO commercially by next quarter.

Highlights a significant market opportunity for the AZO segment due to tariffs against Chinese imports and outlines the strategy to capitalize on it.

Asked by Yashvi

API business profitability challenges despite backward integration Direct
What has not worked in favor of atlas performance is the prices of the products, particularly the main product Pregabalin have really crashed. So, the last whole year has been, we have seen about a 15% decrease in the prices of most of the products.

Explains the primary reason for subdued profitability in the API segment (price erosion) while noting volume growth and the role of backward integration.

Asked by Yashvi

Blue business capacity utilization and gross margin sustainability Direct
So current capacity utilization Rudraksh is about 85-87%... we are confident that we will be able to replicate the gross margin and overall numbers of the blue business going forward as well.

Confirms high capacity utilization in the core blue business and management's confidence in maintaining profitability despite challenging market conditions.

Asked by Rudraksh Raheja

API segment new products and market expansion plans Direct
we plan to do is that we plan to leverage the advantages of Odhav as well as Chhatral units and work as one... we will be looking to add a new segment to our main product by applying for accreditations... we will also be adding new products... over the next two years, we plan to be making them even from a few stages backwards...

Details the strategic roadmap for the API segment, focusing on diversification, certifications, and backward integration for new molecules.

Asked by Rudraksh Raheja

Confidence in strong growth guidance despite geopolitical challenges Direct
we are coming towards the end of a Capex cycle... we've started the deleveraging process... as the utilization improves it will automatically add to the EBITDAs and also decrease our overhead cost... we are thinking that the top line growth will be decent at about 15%, but the EBITDA and the PBT growth would probably be much faster.

Provides the underlying rationale for the ambitious financial guidance, linking it to operational efficiencies, deleveraging, and improved utilization.

Asked by Dhwanil Desai

Impact of anti-dumping duty on AZO pigments from China Direct
So, it's varied from 20 to 30%... the anti-dumping duty is a reality and a 20 to 30% duty on China clearly means that they are not going to be able to they're eventually going to lose the business in India for this volume, whatever they had. So, we will hope to get part of that volume for sure.

Confirms a significant regulatory advantage for domestic AZO producers and indicates potential market share gains from Chinese competitors.

Asked by Sai Ganesh

Improvement in working capital days Direct
in terms of days, if you work out roughly for last week, it was around 130 days and currently it is around 102 days.

Highlights a substantial improvement in working capital management, contributing to stronger cash flow generation.

Asked by Vignesh Iyer

2 min read 6 chapters

Detailed narrative

Strong Financial Turnaround in FY25

Asahi Songwon reported a robust financial performance for FY25, with revenues increasing by 32% to 566 crores from 429 crores in FY24. This growth was accompanied by a significant 185% surge in EBITDA to 60 crores, leading to a doubling of EBITDA margins from 5% to 10%. The company successfully transitioned from a negative PAT in FY24 to a positive PAT of 17 crores in FY25, indicating a strong turnaround in profitability.

Improved Cash Flow and Debt Reduction

The company demonstrated strong cash flow generation, with operating cash flow improving substantially from 9 crores in FY24 to 57 crores in FY25. This was attributed to better management of payables, receivables, and inventory levels. Concurrently, Asahi Songwon focused on deleveraging, reducing its total debt from 200 crores in March 2024 to 160 crores in March 2025. The debt-to-equity ratio improved from 0.75 to 0.55, and EBITDA-to-debt dropped to 2.5 times.

AZO Business: Capitalizing on Tariff Opportunities

The AZO pigment business is set to benefit from anti-dumping duties of 20-30% imposed on Chinese imports, particularly in the US market. Management anticipates commercial opportunities to reflect in performance by the next quarter, with expectations of securing large quantity orders from 1-2 customers by year-end. A new yellow pigment line, involving a capex of approximately 5 crores, is expected to be fully operational within 3-4 months, adding 40 tons to the existing capacity.

API Segment: Diversification Amidst Price Pressure

Despite a challenging environment marked by a ~15% price crash for key API products like Pregabalin, the API segment achieved a 25% increase in volumes. The company is strategically moving towards becoming a multi-product API company, planning to launch new molecules and pursue backward integration for some over the next two years. This strategy aims to enhance profitability and reduce dependency on single products, with a target of 10-11% EBITDA margins for the full year.

Positive Outlook and Growth Targets for FY26

Asahi Songwon provided optimistic guidance for the next financial year (FY26), projecting a 15% top-line growth, 25% EBITDA growth, and 65% PBT growth. The company expects AZO capacity utilization to reach 80-85%, driving a 26-27% top-line growth (from 70 crores to 90 crores) and 8-10% EBITDA for the segment. Overall, consolidated EBITDA margins are targeted at around 12% in the coming years, with a long-term ROCE target of 15%.

Blue Business Stability and Efficiency Focus

The core blue pigment business continues to operate at a high capacity utilization of 85-87%. While the demand environment for pigments remains tepid, management is confident in sustaining gross margins through ongoing engineering and efficiency improvements. This segment is expected to provide stable performance, although significant growth is not anticipated due to the challenging industry landscape.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls